Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol (2013) 1.54

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53

Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol (2015) 0.91

Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense? World J Urol (2016) 0.84

Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. Oncotarget (2015) 0.82

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer (2014) 0.81

Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review). Int J Oncol (2014) 0.77

Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Curr Opin Urol (2013) 0.76

Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: Yes. Int Braz J Urol (2016) 0.75

MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes. Int Braz J Urol (2016) 0.75

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.75

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87

Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24

Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (2001) 3.06

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1998) 2.92

Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res (2001) 2.14

Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene (2009) 2.00

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95

The evolving biology and treatment of prostate cancer. J Clin Invest (2007) 1.81

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68

Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol (2010) 1.66

Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol (2004) 1.64

Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 1.58

African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer (2006) 1.52

Molecular signaling pathways that regulate prostate gland development. Differentiation (2008) 1.47

Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42

The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res (1999) 1.42

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36

A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32

Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer (2009) 1.26

A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol (2003) 1.22

Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate (2000) 1.21

Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol (2001) 1.11

From pathogenesis to prevention of castration resistant prostate cancer. Prostate (2010) 1.09

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer (1999) 1.07

Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate (2005) 1.05

Hedgehog signaling in the prostate. J Urol (2007) 1.04

Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther (2008) 1.04

DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab (2005) 1.03

Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology (1998) 0.99

Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol (2008) 0.99

Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther (2003) 0.97

Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int (2006) 0.92

Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen. J Urol (1998) 0.91

Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate (2008) 0.90

Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J (1999) 0.89

Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol (2009) 0.88

Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int (2006) 0.87

Taxane refractory prostate cancer. J Urol (2007) 0.84

Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology (2007) 0.83

Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer (2009) 0.79

17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review. Anticancer Agents Med Chem (2009) 0.78

Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. Br J Urol (1997) 0.76

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69

Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39

Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06

Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92

Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol (2012) 3.82

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38

Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14

High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol (2008) 3.09

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02

Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52

Bladder cancer. J Natl Compr Canc Netw (2013) 2.46

Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41

Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood (2011) 2.34

Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol (2005) 2.25

Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst (2007) 2.24

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer (2010) 2.19

Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol (2009) 2.18

Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol (2008) 2.16

Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol (2004) 2.10

Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer (2008) 2.07

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol (2013) 2.07

Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol (2008) 2.00

Appalachian mountaintop mining particulate matter induces neoplastic transformation of human bronchial epithelial cells and promotes tumor formation. Environ Sci Technol (2014) 2.00

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol (2008) 1.99

The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform (2009) 1.98

Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98

Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95

Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res (2006) 1.93

Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol (2005) 1.91

Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91

Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol (2009) 1.90

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87

A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74

Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology (2002) 1.74

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med (2011) 1.74

Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74

Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int (2006) 1.70

Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann Thorac Surg (2009) 1.69

Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer (2007) 1.69

Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68

Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res (2012) 1.68

Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68